

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Decitabine for the treatment of acute myeloid leukaemia

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No potential equality issues were identified during the initial scoping process in 2010.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

No potential equality issues were identified during the initial scoping process in 2010 that would need to be addressed by the Committee.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the scope were needed after the initial scoping process in 2010 because no potential equality issues had been identified.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders related to potential equality issues were identified during the initial scoping process in 2010.

Approved by Associate Director: Frances Sutcliffe

Date: 06 09 2012